Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTR-2: Primary Tumor Resection in Oligometastatic EGFR-Mutant NSCLC
NCT07738172Phase 3Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2026
- Primary completion
- Aug 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Progression-Free Survival at 24 months. Started Sep 2026; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07738172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738172.